Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/15/23
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)GlobeNewsWire • 11/13/23
Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell CarcinomaBusiness Wire • 11/13/23
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)Seeking Alpha • 11/11/23
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASHGlobeNewsWire • 11/03/23
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular EdemaGlobeNewsWire • 11/01/23
Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 11/01/23
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain PatientThe Motley Fool • 10/30/23
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing LossGlobeNewsWire • 10/26/23
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)GlobeNewsWire • 10/22/23
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)GlobeNewsWire • 10/21/23
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous UrticariaGlobeNewsWire • 10/20/23
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TNGlobeNewsWire • 10/18/23
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African AncestryBusiness Wire • 10/18/23